These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

640 related items for PubMed ID: 28900703

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB.
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [Abstract] [Full Text] [Related]

  • 3. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG, Gerke O, Baun C, Falch K, Hansen JA, Farahani ZA, Petersen H, Larsen LB, Duvnjak S, Buskevica I, Bektas S, Søe K, Jylling AM, Ewertz M, Alavi A, Høilund-Carlsen PF.
    J Clin Oncol; 2016 Jun 01; 34(16):1889-97. PubMed ID: 27001573
    [Abstract] [Full Text] [Related]

  • 4. Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma.
    Santhosh S, Mittal BR, Bhasin DK, Rana SS, Gupta R, Das A, Nada R.
    Ann Nucl Med; 2017 Oct 01; 31(8):575-581. PubMed ID: 28689356
    [Abstract] [Full Text] [Related]

  • 5. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
    Hamidian Jahromi A, Sangster G, Zibari G, Martin B, Chu Q, Takalkar A, Shi R, Shokouh-Amiri H.
    JOP; 2013 Jul 11; 14(4):466-8. PubMed ID: 23846950
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET/MRI and CA 19-9.
    Yoo J, Lee JM, Joo I, Lee DH, Yoon JH, Yu MH, Jang JY, Lee SH.
    Cancer Imaging; 2023 May 22; 23(1):49. PubMed ID: 37217958
    [Abstract] [Full Text] [Related]

  • 9. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.
    Daamen LA, Groot VP, Goense L, Wessels FJ, Borel Rinkes IH, Intven MPW, van Santvoort HC, Molenaar IQ.
    Eur J Radiol; 2018 Sep 22; 106():128-136. PubMed ID: 30150034
    [Abstract] [Full Text] [Related]

  • 10. 18F-FDG PET/CT in ovarian cancer recurrence: Clinical impact, correlation with ceCT and CA-125, and prognostic value.
    García-Talavera P, Alejo E, Arias P, Verdú A, Tamayo P, Gómez-Caminero F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 Sep 22; 40(4):207-213. PubMed ID: 34218882
    [Abstract] [Full Text] [Related]

  • 11. Three-Dimensional Image Fusion of 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography and Contrast-Enhanced Computed Tomography for Computer-Assisted Planning of Maxillectomy of Recurrent Maxillary Squamous Cell Carcinoma and Defect Reconstruction.
    Yu Y, Zhang WB, Liu XJ, Guo CB, Yu GY, Peng X.
    J Oral Maxillofac Surg; 2017 Jun 22; 75(6):1301.e1-1301.e15. PubMed ID: 28320612
    [Abstract] [Full Text] [Related]

  • 12. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and 18F-FDG PET/CT.
    Jeong B, Oh M, Lee SS, Kim N, Kim JS, Lee W, Kim SC, Kim HJ, Kim JH, Byun JH.
    Korean J Radiol; 2024 Jul 22; 25(7):644-655. PubMed ID: 38942458
    [Abstract] [Full Text] [Related]

  • 13. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun 22; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G, Altini C, Notaristefano A, Merenda N, Rubini D, Ianora AA, Asabella AN.
    Rev Esp Med Nucl Imagen Mol; 2014 Jun 22; 33(1):22-7. PubMed ID: 23948509
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.